Status:
UNKNOWN
Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris
Lead Sponsor:
Sohag University
Conditions:
Verruca Vulgaris
Healthy
Eligibility:
All Genders
1+ years
Brief Summary
This study aims to assess the expression of SCCA2 in the skin of patients with warts and to detect its correlation with characteristics of warts.
Detailed Description
Type of the study: Cross sectional study. Patients: This study will include 25 patients with verruca vulgaris and 25 healthy volunteers. Inclusion criteria: Patients present with warts (verruca vulg...
Eligibility Criteria
Inclusion
- Patients present with warts (verruca vulgaris type).
Exclusion
- Subjects who presenting with allergic diseases or other dermatological diseases or had a history of squamous cell carcinoma will be excluded from this study.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05409365
Start Date
May 1 2022
End Date
January 1 2023
Last Update
June 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sohag University
Sohag, Egypt